Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1681/ASN.2013030251 http://scihub22266oqcxt.onion/10.1681/ASN.2013030251 C3968490!3968490!24480824     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Am+Soc+Nephrol 2014 ; 25 (4): 850-63 Nephropedia Template TP {{tp|p=24480824|t=2014. Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome |pdf=|usr=}}{{24480824}} gab.com Text Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome JO: J Am Soc Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=24480824 #FOAvip The outcome of steroid-dependent or frequently relapsing nephrotic syndrome of minimal change disease (MCD), mesangial proliferative GN (MesGN), or FSGS may be poor and with major treatment toxicity. This academic, multicenter, off-on trial (ClinicalTrials.gov #NCT00981838) primarily evaluated the effects of rituximab therapy followed by immunosuppression withdrawal on disease recurrence in 10 children and 20 adults with MCD/MesGN (n=22) or FSGS who had suffered ?2 recurrences over the previous year and were in steroid-induced remission for ?1 month. Participants received one dose (n=28) or two doses of rituximab (375 mg/m2 intravenously). At 1 year, all patients were in remission: 18 were treatment-free and 15 never relapsed. Compared with the year before rituximab treatment, total relapses decreased from 88 to 22 and the per-patient median number of relapses decreased from 2.5 (interquartile range [IQR], 2?4) to 0.5 (IQR, 0?1; P<0.001) during 1 year of follow-up. Reduction was significant across subgroups (children, adults, MCD/MesGN, and FSGS; P<0.01). After rituximab, the per-patient steroid maintenance median dose decreased from 0.27 mg/kg (IQR, 0.19?0.60) to 0 mg/kg (IQR, 0?0.23) (P<0.001), and the median cumulative dose to achieve relapse remission decreased from 19.5 mg/kg (IQR, 13.0?29.2) to 0.5 mg/kg (IQR, 0?9.4) (P<0.001). Furthermore, the mean estimated GFR increased from 111.3±25.7 to 121.8±29.2 ml/min per 1.73 m2 (P=0.01), with the largest increases in children and in FSGS subgroups. The mean height z score slope stabilized in children (P<0.01). Treatment was well tolerated. Rituximab effectively and safely prevented recurrences and reduced the need for immunosuppression in steroid-dependent or frequently relapsing nephrotic syndrome, and halted disease-associated growth deficit in children. Twit Text FOAVip Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome ????J Am Soc Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=24480824 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24480824 #FOAvip English Wikipedia <ref>{{Cite pmid|24480824}}</ref> Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome #MMPMID24480824 Ruggenenti P; Ruggiero B; Cravedi P; Vivarelli M; Massella L; Marasà M; Chianca A; Rubis N; Ene-Iordache B; Rudnicki M; Pollastro RM; Capasso G; Pisani A; Pennesi M; Emma F; Remuzzi G J Am Soc Nephrol 2014[Apr]; 25 (4): 850-63 PMID24480824show ga The outcome of steroid-dependent or frequently relapsing nephrotic syndrome of minimal change disease (MCD), mesangial proliferative GN (MesGN), or FSGS may be poor and with major treatment toxicity. This academic, multicenter, off-on trial (ClinicalTrials.gov #NCT00981838) primarily evaluated the effects of rituximab therapy followed by immunosuppression withdrawal on disease recurrence in 10 children and 20 adults with MCD/MesGN (n=22) or FSGS who had suffered ?2 recurrences over the previous year and were in steroid-induced remission for ?1 month. Participants received one dose (n=28) or two doses of rituximab (375 mg/m2 intravenously). At 1 year, all patients were in remission: 18 were treatment-free and 15 never relapsed. Compared with the year before rituximab treatment, total relapses decreased from 88 to 22 and the per-patient median number of relapses decreased from 2.5 (interquartile range [IQR], 2?4) to 0.5 (IQR, 0?1; P<0.001) during 1 year of follow-up. Reduction was significant across subgroups (children, adults, MCD/MesGN, and FSGS; P<0.01). After rituximab, the per-patient steroid maintenance median dose decreased from 0.27 mg/kg (IQR, 0.19?0.60) to 0 mg/kg (IQR, 0?0.23) (P<0.001), and the median cumulative dose to achieve relapse remission decreased from 19.5 mg/kg (IQR, 13.0?29.2) to 0.5 mg/kg (IQR, 0?9.4) (P<0.001). Furthermore, the mean estimated GFR increased from 111.3±25.7 to 121.8±29.2 ml/min per 1.73 m2 (P=0.01), with the largest increases in children and in FSGS subgroups. The mean height z score slope stabilized in children (P<0.01). Treatment was well tolerated. Rituximab effectively and safely prevented recurrences and reduced the need for immunosuppression in steroid-dependent or frequently relapsing nephrotic syndrome, and halted disease-associated growth deficit in children. äRituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Neph(epmc).pdf DeepDyve Pubget Overpricing